Rivaroxaban Zentiva20 mg hard capsules
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Rivaroxaban Zentiva contains the active substance rivaroxaban and is used in adults to:
Rivaroxaban Zentiva belongs to a group of medicines called antithrombotic agents. It works by blocking a factor involved in blood clotting (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Zentiva
Do not take Rivaroxaban Zentiva and inform your doctor if any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Rivaroxaban Zentiva.
Be careful with Rivaroxaban Zentiva
Tell your doctorif you have any of these situationsbefore taking Rivaroxaban Zentiva. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
Children and adolescents
Rivaroxaban Zentiva 20 mg is not recommended for persons under 18 years of age. There is not enough information available on the use of rivaroxaban in children and adolescents for the indications in adults.
Other medications and Rivaroxaban Zentiva
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of these circumstances apply to you, tell your doctorbefore taking Rivaroxaban Zentiva, as the effect of Rivaroxaban Zentiva may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they may recommend using a preventive treatment for ulcers in addition.
If any of these circumstances apply to you,tell your doctorbefore taking Rivaroxaban Zentiva, as the effect of Rivaroxaban Zentiva may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take Rivaroxaban Zentiva if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking Rivaroxaban Zentiva. If you become pregnant while taking this medication, tell your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban Zentiva may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4 "Possible side effects"). You should not drive or use machines if you are affected by these symptoms.
Rivaroxaban Zentiva 20 mg contains lactose, sodium, and carmoisine (E 122)
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially "sodium-free".
The excipient carmoisine (E 122) may cause allergic reactions.
Follow the instructions for administration of this medication exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
You must take Rivaroxaban Zentiva with food.
Swallow the capsule, preferably with water.
If you have difficulty swallowing the capsule whole, consult your doctor about other ways to take Rivaroxaban Zentiva. The contents of the capsule can be mixed with water or apple sauce immediately before taking it. This mixture should be followed immediately by food.
If necessary, your doctor may also administer the contents of the Rivaroxaban Zentiva capsule through a gastric tube.
What dose to take
The recommended dose is one Rivaroxaban Zentiva 20 mg capsule once a day.
If you have kidney problems, the dose may be reduced to one Rivaroxaban Zentiva 15 mg capsule once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent insertion), there is limited evidence to reduce the dose to one Rivaroxaban Zentiva 15 mg capsule once a day (or to one Rivaroxaban Zentiva 10 mg capsule once a day if your kidneys do not function properly) in addition to an antiplatelet medication such as clopidogrel.
The recommended dose is one Rivaroxaban Zentiva 15 mg capsule twice a day for the first 3 weeks.
For treatment after 3 weeks, the recommended dose is one Rivaroxaban Zentiva 20 mg capsule once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg capsule once a day or one 20 mg capsule once a day.
If you have kidney problems and are taking one Rivaroxaban Zentiva 20 mg capsule once a day, your doctor may decide to reduce the treatment dose to one Rivaroxaban Zentiva 15 mg capsule once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
If you spit out the dose or vomit
Contact your doctor if you spit out the dose or vomit repeatedly after taking Rivaroxaban Zentiva.
When to take Rivaroxaban Zentiva
Take the capsule every day, until your doctor tells you to stop.
Try to take the capsule at the same time every day to remember when to take it.
Your doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the brain (stroke) or in other blood vessels:
If it is necessary to normalize your heartbeat through a procedure called cardioversion, take Rivaroxaban Zentiva at the times indicated by your doctor.
If you take more Rivaroxaban Zentiva than you should
Call your doctor immediately if you have taken too many Rivaroxaban Zentiva capsules. Taking too much Rivaroxaban Zentiva increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Rivaroxaban Zentiva
If you interrupt treatment with Rivaroxaban Zentiva
Do not interrupt treatment with Rivaroxaban Zentiva without consulting your doctor first, as Rivaroxaban Zentiva treats and prevents serious conditions.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Rivaroxaban Zentiva can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, Rivaroxaban Zentiva can cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you or your child suffers from any of the following adverse effects:
Your doctor will decide to keep you under closer observation or modify your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
Severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects
Frequent(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from the available data)
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on the blister pack after "CAD". The expiration date is the last day of the month indicated.
Alu/Alu blisters: No special storage conditions are required.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines you no longer need at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Rivaroxaban Zentiva
Capsule content: lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, hypromellose, sodium lauryl sulfate, and magnesium stearate.
Capsule shell: gelatin, titanium dioxide (E 171), quinoline yellow (E 104), carmoisine (E 122), and patent blue V (E 131).
White ink: esterified lacquer, propylene glycol (E 1520), and titanium dioxide (E 171).
Appearance of the product and package contents
Rivaroxaban Zentiva 20 mg capsules are a white to off-white powder packaged in size "0" (21.7 ± 0.3 mm in length) capsules with a dark brown opaque cap and body with the imprint "20" in white ink.
The hard capsules are packaged in PVC/PVdC/Alu or Alu/Alu blisters.
Rivaroxaban Zentiva 20 mg is available in packages of 14, 28, 30, 98, or 100 hard capsules.
Only some package sizes may be marketed.
Marketing authorization holder
Zentiva k.s.
U Kabelovny 130,
Dolní Mecholupy
102 37 Prague 10
Czech Republic
Manufacturer
Zentiva SA
B-dul Theodor Pallady nr. 50, sector 3,
Bucharest,
032266 Romania
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park,
Paola, PLA3000, Malta
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Zentiva Spain S.L.U.
Avenida de Europa, 19, Edificio 3, Planta 1.
28224 Pozuelo de Alarcón, Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Czech Republic, Germany, and Italy: Rivaroxaban Zentiva
France: Rivaroxaban ZENTIVA
Portugal: Rivaroxabano Zentiva
Date of the last revision of this prospectus:October 2023.
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es